• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甘油三酯与高密度脂蛋白胆固醇比值作为首次经皮冠状动脉介入治疗后急性冠状动脉综合征患者再次血运重建的危险因素。

Triglyceride to high-density lipoprotein cholesterol ratio as a risk factor of repeat revascularization among patients with acute coronary syndrome after first-time percutaneous coronary intervention.

作者信息

Su Ya-Min, Zhang Rui, Xu Rong-Feng, Wang Hong-Lei, Geng Hai-Hua, Pan Min, Qu Yang-Yang, Zuo Wen-Jie, Ji Zhen-Jun, Ma Gen-Shan

机构信息

Department of Cardiology, School of Medicine, Southeast University, Nanjing 210009, China.

Department of Cardiology, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang 471003, China.

出版信息

J Thorac Dis. 2019 Dec;11(12):5087-5095. doi: 10.21037/jtd.2019.12.26.

DOI:10.21037/jtd.2019.12.26
PMID:32030225
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6988028/
Abstract

BACKGROUND

It is clinically important to identify high-risk patients with acute coronary syndrome (ACS) who may require repeat revascularization. This retrospective study identified risk factors for repeat revascularization among ACS patients after first-time successful percutaneous coronary interventions (PCIs). The predictive value of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio for repeat revascularization was also evaluated.

METHODS

We enrolled consecutive ACS patients who had coronary angiography performed during the period from 6 to 12 months after a first-time successful PCI. The primary outcome of the study was to identify the risk factors of repeat revascularization. The subjects were stratified based on repeat PCI events. After comparing various clinical characteristics, univariate and multivariate Cox proportional hazard model analyses were adopted to evaluate the effects of risk factors on repeat revascularization.

RESULTS

The patients (n=271) were divided into the event (+) group (n=101) and the event (-) group (n=170). In the event (+) group, target lesion revascularization (TLR) accounted for 20.79% and target vessel revascularization (TVR) accounted for 50.49% of the patients. In contrast, 52.47% of the patients required vessel revascularization (DVR). After adjustment for confounding factors, the TG/HDL-C ratio [hazard ratio (HR) =1.206, 95% confidence interval (CI): 1.016-1.431, P=0.032 for each higher TG/HDL-C ratio unit] and the Gensini score (HR =1.012, 95% CI: 1.005-1.018, P<0.001 for each higher Gensini score unit) were independent risk factors for a repeat PCI. Subgroup analyses showed that higher TG/HDL-C ratios were associated with a significantly higher risk of repeat PCIs in the male, hypertensive, and diabetes mellitus subgroups.

CONCLUSIONS

The TG/HDL-C ratio and Gensini score could serve as risk factors for repeat revascularization in ACS patients after a first-time successful PCI.

摘要

背景

识别可能需要再次血运重建的急性冠状动脉综合征(ACS)高危患者具有重要的临床意义。这项回顾性研究确定了首次成功进行经皮冠状动脉介入治疗(PCI)后ACS患者再次血运重建的危险因素。还评估了甘油三酯与高密度脂蛋白胆固醇(TG/HDL-C)比值对再次血运重建的预测价值。

方法

我们纳入了在首次成功PCI后6至12个月期间进行冠状动脉造影的连续ACS患者。该研究的主要结局是确定再次血运重建的危险因素。根据再次PCI事件对受试者进行分层。在比较各种临床特征后,采用单因素和多因素Cox比例风险模型分析来评估危险因素对再次血运重建的影响。

结果

患者(n = 271)分为事件(+)组(n = 101)和事件(-)组(n = 170)。在事件(+)组中,靶病变血运重建(TLR)占患者的20.79%,靶血管血运重建(TVR)占患者的50.49%。相比之下,52.47%的患者需要进行非靶血管血运重建(DVR)。在调整混杂因素后,TG/HDL-C比值[风险比(HR)= 1.206,95%置信区间(CI):1.016 - 1.431,每增加一个TG/HDL-C比值单位P = 0.032]和Gensini评分(HR = 1.012,95%CI:1.005 - 1.018,每增加一个Gensini评分单位P < 0.001)是再次PCI的独立危险因素。亚组分析表明,在男性、高血压和糖尿病亚组中,较高的TG/HDL-C比值与再次PCI的风险显著升高相关。

结论

TG/HDL-C比值和Gensini评分可作为首次成功PCI后ACS患者再次血运重建的危险因素。

相似文献

1
Triglyceride to high-density lipoprotein cholesterol ratio as a risk factor of repeat revascularization among patients with acute coronary syndrome after first-time percutaneous coronary intervention.甘油三酯与高密度脂蛋白胆固醇比值作为首次经皮冠状动脉介入治疗后急性冠状动脉综合征患者再次血运重建的危险因素。
J Thorac Dis. 2019 Dec;11(12):5087-5095. doi: 10.21037/jtd.2019.12.26.
2
[Correlation between neutrophil/lymphocyte ratio combined with low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and severity of coronary artery disease in patients with acute coronary syndrome].[中性粒细胞/淋巴细胞比值联合低密度脂蛋白胆固醇/高密度脂蛋白胆固醇比值与急性冠状动脉综合征患者冠状动脉疾病严重程度的相关性]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022 Mar;34(3):274-279. doi: 10.3760/cma.j.cn121430-20211008-01441.
3
Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation.评估 LDL-C/HDL-C 比值对经皮冠状动脉介入治疗和药物洗脱支架置入术后急性冠脉综合征患者一年临床结局的预测价值。
Lipids Health Dis. 2019 Feb 2;18(1):40. doi: 10.1186/s12944-019-0979-6.
4
Triglyceride to high density lipoprotein cholesterol ratio may serve as a useful predictor of major adverse coronary event in female revascularized ST-elevation myocardial infarction.甘油三酯与高密度脂蛋白胆固醇比值可作为女性经皮冠状动脉介入治疗 ST 段抬高型心肌梗死患者主要不良冠状动脉事件的有用预测指标。
Clin Chim Acta. 2018 Oct;485:166-172. doi: 10.1016/j.cca.2018.06.049. Epub 2018 Jun 30.
5
The association between triglyceride/high-density lipoprotein cholesterol ratio and all-cause mortality in acute coronary syndrome after coronary revascularization.冠状动脉血运重建术后急性冠脉综合征患者甘油三酯/高密度脂蛋白胆固醇比值与全因死亡率的关联
PLoS One. 2015 Apr 16;10(4):e0123521. doi: 10.1371/journal.pone.0123521. eCollection 2015.
6
Relationship between lipoprotein(a) and revascularization after percutaneous coronary intervention in type 2 diabetes mellitus patients with acute coronary syndrome.2型糖尿病合并急性冠脉综合征患者经皮冠状动脉介入治疗后脂蛋白(a)与血管重建的关系。
Curr Med Res Opin. 2022 Oct;38(10):1663-1672. doi: 10.1080/03007995.2022.2078080. Epub 2022 May 26.
7
Impact of nonfasting triglycerides/high-density lipoprotein cholesterol ratio on secondary prevention in patients treated with statins.非空腹甘油三酯/高密度脂蛋白胆固醇比值对他汀类药物治疗患者二级预防的影响。
J Cardiol. 2018 Jan;71(1):10-15. doi: 10.1016/j.jjcc.2017.07.012. Epub 2017 Sep 12.
8
Association of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and major adverse cardiac and cerebrovascular events in patients with coronary heart disease undergoing percutaneous coronary intervention: a cohort study.低密度脂蛋白胆固醇与高密度脂蛋白胆固醇比值与经皮冠状动脉介入治疗的冠心病患者主要不良心脏和脑血管事件的关系:一项队列研究。
Curr Med Res Opin. 2023 Sep;39(9):1175-1181. doi: 10.1080/03007995.2023.2246889. Epub 2023 Aug 24.
9
Intravascular ultrasound to guide percutaneous coronary interventions: an evidence-based analysis.血管内超声引导经皮冠状动脉介入治疗:一项基于证据的分析。
Ont Health Technol Assess Ser. 2006;6(12):1-97. Epub 2006 Apr 1.
10
Contributors to newly developed coronary artery disease in patients with a previous history of percutaneous coronary intervention beyond the early phase of restenosis.既往有经皮冠状动脉介入治疗病史的患者,在再狭窄早期阶段之后新发冠状动脉疾病的相关因素。
Intern Med. 2014;53(8):819-28. doi: 10.2169/internalmedicine.53.1438. Epub 2014 Apr 15.

引用本文的文献

1
Triglyceride to high-density lipoprotein ratio as a predictor for 10-year cardiovascular disease in individuals with diabetes in Thailand.甘油三酯与高密度脂蛋白比值作为泰国糖尿病患者10年心血管疾病的预测指标。
J Health Popul Nutr. 2025 May 9;44(1):147. doi: 10.1186/s41043-025-00835-0.
2
The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease.甘油三酯/高密度脂蛋白胆固醇(TG/HDL-C)比值作为代谢综合征和心血管疾病的风险标志物
Diagnostics (Basel). 2023 Mar 1;13(5):929. doi: 10.3390/diagnostics13050929.
3
Association between nontraditional lipid profiles and peripheral arterial disease in Chinese adults with hypertension.非传统血脂谱与高血压中国成年人外周动脉疾病的关系。
Lipids Health Dis. 2020 Nov 3;19(1):231. doi: 10.1186/s12944-020-01407-3.

本文引用的文献

1
Long-term (5-year) clinical evaluation of the Resolute zotarolimus-eluting coronary stent: The RESOLUTE US clinical trial.Resolute 佐他莫司洗脱冠状动脉支架的 5 年长期临床评估:RESOLUTE US 临床试验。
Catheter Cardiovasc Interv. 2020 May 1;95(6):1067-1073. doi: 10.1002/ccd.28392. Epub 2019 Jul 13.
2
Incidence and predictors of target lesion failure in patients undergoing contemporary DES implantation-Individual patient data pooled analysis from 6 randomized controlled trials.当代 DES 植入术后患者靶病变失败的发生率及预测因素——来自 6 项随机对照试验的个体患者数据汇总分析。
Am Heart J. 2019 Jul;213:105-111. doi: 10.1016/j.ahj.2019.03.011. Epub 2019 Apr 12.
3
Associations of non-high-density lipoprotein cholesterol, triglycerides and the total cholesterol/HDL-c ratio with arterial stiffness independent of low-density lipoprotein cholesterol in a Chinese population.在中国人群中,非高密度脂蛋白胆固醇、甘油三酯和总胆固醇/高密度脂蛋白胆固醇比值与动脉僵硬度的相关性独立于低密度脂蛋白胆固醇。
Hypertens Res. 2019 Aug;42(8):1223-1230. doi: 10.1038/s41440-019-0251-5. Epub 2019 Mar 27.
4
Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.依维莫司洗脱生物可吸收支架治疗糖尿病患者冠状动脉疾病:前瞻性 ABSORB DM 比荷卢研究的中期随访。
Cardiovasc Diabetol. 2019 Mar 9;18(1):25. doi: 10.1186/s12933-019-0827-z.
5
Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.载有西罗莫司的超小厚度冠状动脉支架治疗动脉粥样硬化性病变的安全性和有效性(TALENT):一项前瞻性多中心随机对照试验。
Lancet. 2019 Mar 9;393(10175):987-997. doi: 10.1016/S0140-6736(18)32467-X. Epub 2019 Feb 28.
6
Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation.评估 LDL-C/HDL-C 比值对经皮冠状动脉介入治疗和药物洗脱支架置入术后急性冠脉综合征患者一年临床结局的预测价值。
Lipids Health Dis. 2019 Feb 2;18(1):40. doi: 10.1186/s12944-019-0979-6.
7
'Ten commandments' for the 2018 ESC/EACTS Guidelines on Myocardial Revascularization.2018年欧洲心脏病学会/欧洲心胸外科学会心肌血运重建指南的“十诫”
Eur Heart J. 2019 Jan 7;40(2):79-80. doi: 10.1093/eurheartj/ehy855.
8
Bivalirudin versus heparin in percutaneous coronary intervention-a systematic review and meta-analysis of randomized trials stratified by adjunctive glycoprotein IIb/IIIa strategy.比伐卢定与肝素用于经皮冠状动脉介入治疗——一项根据辅助糖蛋白IIb/IIIa策略分层的随机试验的系统评价和荟萃分析
J Thorac Dis. 2018 Jun;10(6):3341-3360. doi: 10.21037/jtd.2018.05.76.
9
Should ultrathin strut drug eluting stents be considered the new benchmark for novel coronary stents approval? The complex interplay between stent strut thickness, polymeric carriers and antiproliferative drugs.超薄支柱药物洗脱支架应被视为新型冠状动脉支架获批的新基准吗?支架支柱厚度、聚合物载体和抗增殖药物之间的复杂相互作用。
J Thorac Dis. 2018 Feb;10(2):678-681. doi: 10.21037/jtd.2018.01.108.
10
Novel treatments for in-stent restenosis: sirolimus-eluting balloons enter the arena.支架内再狭窄的新型治疗方法:西罗莫司洗脱球囊进入竞争领域。
J Thorac Dis. 2018 Feb;10(2):628-630. doi: 10.21037/jtd.2018.01.04.